Identification of a Guinea Pig Fcγ Receptor that Exhibits Enhanced Binding to Afucosylated Human and Mouse IgG.

ABSTRACT: Glyco-engineered recombinant antibodies are currently being developed as the next generation therapeutics to treat human diseases, including cancer, autoimmunity and infection. Antibodies lacking core fucosylation show great increase in affinity for FcγRIIIA, leading to an improved receptor-mediated effector function. While afucosyl human IgG1 exhibits 50-100-fold increase in antibody-mediated cellular cytotoxicity (ADCC), a key immune effector mechanism underlying the anti-cancer effect of some approved therapeutic antibodies, it is not clear whether such glyco-engineered antibodies would find similar use for infectious disease. Due to the species difference, human antibodies may have different binding properties towards corresponding IgG receptors from animals used for modeling infection

SUBMITTER: Mao C 

PROVIDER: S-EPMC8315562 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature